Macrolides provide survival benefit in bacteremic pneumococcal pneumonia

Takeaway

• Macrolide empirical therapy administered reduces mortality risk by as much as 45% in hospitalised patients with culture-confirmed bacteremic pneumococcal pneumonia (BPP).

Why this matters

• Consider azithromycin or roxithromycin in combination with β-lactam therapy to...